FDA approves first drug for infantile spasms

Aug 21, 2009

(AP) -- The Food and Drug Administration has approved the first drug to treat infantile spasms, a rare disorder that can cause hundreds of seizures per day in children less than a year old.

Sabril is an oral solution from Deerfield, Ill.-based Lundbeck Inc. approved for children between the ages of 1 month and 2 years. Infantile spasms usually occur while babies are eating or waking up, and often come in clusters of up to 100.

FDA director of neurology products Russell Katz says: " in this young are very serious and this approval provides these patients and their parents a treatment option."

The FDA also approved a Sabril tablet to treat seizures in adults who have not responded to other drugs.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: FDA approves hard-to-abuse narcotic painkiller

add to favorites email to friend print save as pdf

Related Stories

Diet may eliminate spasms for infants with epilepsy

Sep 08, 2008

Infantile spasms are a severe and potentially devastating epilepsy condition affecting children aged typically 4-8 months. In a new study appearing in Epilepsia, researchers have found that the ketogenic diet, a high fat, l ...

FDA OKs Amitiza for treatment of IBS-C

Apr 30, 2008

The U.S. Food and Drug Administration announced approval of Amitiza (lubiprostone) to treat constipation associated with irritable bowel syndrome.

FDA OKs 50th & 51st anti-retroviral drugs

Aug 14, 2007

The U.S. Food and Drug Administration has tentatively approved nevirapine tablets and a pediatric medication used to treat the human immunodeficiency virus.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

3 hours ago

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

3 hours ago

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

4 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

4 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

22 hours ago

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments : 0